News

PharmaTher Secures FDA Approval for KETARx™ Ketamine Therapy

PharmaTher Secures FDA Approval for KETARx™ Ketamine Therapy

PharmaTher Achieves FDA Approval for KETARx™

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is thrilled to announce the approval of KETARx™, its innovative ketamine-based product, by the U.S. Food and Drug Administration (FDA). This landmark achievement is a game-changer in surgical pain management and establishes PharmaTher’s standing as a key player in the burgeoning psychedelic pharmaceutical market.

CEO's Vision for the Future

Fabio Chianelli, the driving force behind PharmaTher and its CEO, expressed his enthusiasm regarding this monumental achievement. He stated, "Today marks a new chapter for PharmaTher. Having secured FDA approval for KETARx™, we are poised to become a global leader in the ketamine pharmaceutical sector." His comments underscore the Company’s dedication to leveraging ketamine's potential across various therapeutic areas, particularly in addressing mental health, neurological issues, and pain management.

The Expanding Ketamine Market

Ketamine is unique in the world of psychedelics. It holds a distinguished place on the World Health Organization's Model List of Essential Medicines, which recognizes its importance. The global market for ketamine is currently valued at around $750 million and is projected to soar to $3.42 billion by 2034, representing an impressive compound annual growth rate of 16.4%. With the success of related products, such as SPRAVATO® (esketamine), which is expected to generate significant revenue, the landscape for ketamine-based therapies is filled with potential.

Strategic Development Areas

Part of PharmaTher’s strategy includes developing KETARx™ to target a broad spectrum of therapeutic avenues. These include tackling mental health conditions such as depression and neurodegenerative disorders like Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, KETARx™ is positioned to address chronic and rare pain management issues, including Complex Regional Pain Syndrome (CRPS).

The Urgent Need for Reliable Ketamine Supply

Since February 2018, ketamine has consistently appeared on the FDA’s drug shortage list. This situation has led to a pressing need for a reliable supply of high-quality ketamine products. The FDA issued a risk alert highlighting concerns around compounded ketamine products and their use in psychiatric treatment, emphasizing the importance of approved therapies like KETARx™.

Supporting Mental Health Initiatives for Veterans

The focus on mental health support extends to veterans, who often face significant challenges related to PTSD, chronic pain, and depression. The Veterans Health Administration has endorsed and funds ketamine infusions, recognizing their effectiveness for military personnel. This initiative aligns with the larger mission of expanding legal access to psychedelic therapies to provide comprehensive relief for those in need.

Looking Ahead with Confidence

The FDA’s approval of KETARx™ reinforces PharmaTher’s commitment to innovation in the pharmaceutical sector. Recent initiatives by FDA Commissioner Marty Makary to expedite access to effective treatments imply that KETARx™ may enjoy further regulatory support, enhancing its availability for patients.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. is dedicated to unlocking the pharmaceutical benefits of ketamine for mental health, neurological, and pain disorders. As they move forward with KETARx™, the Company remains committed to improving patient outcomes and advancing therapeutic options.

For any inquiries concerning PharmaTher Holdings Ltd., please reach out to:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Frequently Asked Questions

What is KETARx™?

KETARx™ is PharmaTher's ketamine-based product intended for managing surgical pain and potentially addressing various mental health disorders.

How does FDA approval impact PharmaTher?

FDA approval is a significant milestone that validates PharmaTher's efforts and opens doors for expanded clinical development and market opportunities.

What are the benefits of ketamine in mental health?

Ketamine has shown promise in treating mental health conditions like depression and PTSD by providing rapid relief for some patients.

Is there a shortage of ketamine products?

Yes, ketamine has frequently appeared on the FDA's drug shortage list, highlighting the need for reliable sources of this medication.

What is the future outlook for ketamine therapies?

The global ketamine market is projected to grow significantly, fueled by increasing acceptance of its use in mental health treatment and pain management.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 104

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 25

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 57

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 83

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 116

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Foresight Solar Insurance Trial Beats Fixed PPA Route

Updated Category News Views 33

Six solar sites and one settled insurance contract have produced a result worth studying, not celebrating with confetti. Foresight and Paratus say their completed renewable-price insurance policy generated a £14.49/MWh net uplift, after premium, against the revenue those assets would have earned under a fixed-price power purchase agreement. In a UK renewables market...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Datamars Innovates Textile Sorting with New RFID Sorti-Cart

Updated Category News Views 169

Revolutionizing Textile Management in Retirement Homes Datamars has recently made a significant impact on the textile management industry with the introduction of their innovative UHF Sorti-Cart. This cutting-edge RFID trolley is specially crafted for collecting and sorting soiled textiles in retirement homes, addressing a common issue: the loss of personal garments...

Continue Reading
Investigating Potential Securities Claims for WAL Investors

Updated Category News Views 216

Rosen Law Firm Investigates Securities Claims for WAL Investors The Rosen Law Firm, renowned for protecting investor rights, is currently investigating securities claims concerning Western Alliance Bancorporation (NYSE: WAL). The inquiry roots from reports that the company might have disseminated materially misleading business information to its shareholders. Your Rights...

Continue Reading
Leadership Changes at Marten Transport: A New Chapter Ahead

Updated Category News Views 196

Significant Leadership Transition at Marten Transport Marten Transport, Ltd. (Nasdaq: MRTN) has announced a pivotal leadership change as Timothy Kohl, their esteemed Chief Executive Officer, prepares to retire on September 30, 2025. This transition signifies a new chapter for the company, with Randolph Marten stepping into the roles of Chairman of the Board and Chief...

Continue Reading
Enhancing Global Trade: Made-in-China.com's Sourcing Season

Updated Category News Views 175

Made-in-China.com Launches Golden Sourcing Season Made-in-China.com has unveiled its annual Golden Sourcing Season, an initiative designed to energize global procurement. This exciting event provides international buyers the chance to interact with trusted Chinese suppliers, negotiate competitive deals, and efficiently source a wide array of products. Although this annual...

Continue Reading
Meridian Health Plan Invests $15 Million to Enhance Care Quality

Updated Category News Views 301

Meridian Health Plan Enhances Care Quality with Major Investment Meridian Health Plan of Illinois (NYSE: CNC) is making significant strides in the healthcare industry by investing $15 million into initiatives focused on improving health outcomes. This substantial financial commitment is aimed at enhancing the quality of care provided to over 340,000 Medicaid members...

Continue Reading